

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

209091Orig1s000

PRODUCT QUALITY REVIEW(S)



Recommendation:

APPROVAL

(including the Overall Manufacturing Inspection Recommendation)

**NDA 209091
Review #1
Review Date (see last page)**

Drug Name/Dosage Form	saxagliptin and dapagliflozin tablets
Strength	5/10 mg/mg
Route of Administration	oral
Rx/OTC Dispensed	Rx
Applicant	Astra Zeneca

SUBMISSION(S) REVIEWED	DOCUMENT DATE
0000	4/27/2016

Quality Review Team

DISCIPLINE	REVIEWER	DIVISION/OFFICE
Application Technical Lead	Suong (Su) Tran	New Drug Products II/ONDP
Regulatory Business Process Manager	Anika Lalmansingh	Regulatory Business Process Management I/OPRO
Drug Product	John Amartey	New Drug Products II/ONDP
Facility	Vipulchandra Dholakia	Inspectional Assessment/OPF

Quality Review Data Sheet

1. RELATED/SUPPORTING DOCUMENTS:

A. DMFs: Adequate (see OPQ review of NDA (b) (4))

B. Other Documents:

DOCUMENT	APPLICATION	DESCRIPTION
NDA	(b) (4)	saxagliptin and dapagliflozin tablets (same product, same applicant)

2. CONSULTS: not applicable

Executive Summary

I. Recommendation and Conclusion on Approvability

The recommendation from the Office of Pharmaceutical Quality (including the 11/21/16 Overall Manufacturing Inspection Recommendation) is for **APPROVAL**.

II. Summary of Quality Assessment


A. Product Overview

This is a 505(b)(1) application for a fixed dose combination of two approved drug substances, saxagliptin and dapagliflozin, 5 mg and 10 mg. This is not an NME application because the applicant has several approved NDAs for these drug substances.

The same product in this new NDA was previously submitted in NDA (b) (4) by the same applicant. NDA (b) (4) received a Complete Response on 10/15/2015 (b) (4). (b) (4) OPQ review recommended "approval" at the time of the action with no pending Quality issue.

B. Quality Assessment Overview

The CMC information in the new NDA and the previously reviewed NDA (b) (4) (b) (4)



The OPQ review of NDA 209091 consists of the drug product review of the new and updated information listed above and a cross-reference to the OPQ review of NDA (b) (4) for the evaluation of all other Quality information. The Overall Manufacturing Inspection Recommendation is updated on 11/21/16 for “approval”.

Application Technical Lead Signature:

Suong (Su) Tran, Ph.D.
electronic signature on the last page

CHAPTERS: Primary Quality Assessment

- Chapter I: Drug Substance (see OPQ Review of NDA (b)(4))
Chapter II: Drug Product
Chapter III: Environmental Assessment (see OPQ Review of NDA (b)(4))
Chapter IV: Labeling
Chapter V: Process (see OPQ Review of NDA (b)(4))
Chapter VI: Facilities (see OPQ Review of NDA (b)(4))
Chapter VII: Biopharmaceutics (see OPQ Review of NDA (b)(4))
Chapter VIII: Microbiology (see OPQ Review of NDA (b)(4))
Attachment I: Final Risk Assessment (see OPQ Review of NDA (b)(4))

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.